Acute Lymphoblastic Leukemia – Unmet Need – Detailed, Expanded Analysis: Relapsed or Refractory Philadelphia Chromosome-Negative ALL (US/EU)

Relapsed / refractory (R/R) Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) patients have a poor prognosis. No standard of care has been established for relapsed / refractory ALL, and thus treatment remains a challenge. The mainstay of therapy is chemotherapy such as that used in the first line. The approval of therapies such as Amgen’s Blincyto, Pfizer’s Besponsa, and the CD19-targeted CAR T-cell therapies Kymriah (Novartis) and Tecartus (Kite Pharma / Gilead Sciences) have expanded the treatment options, but these agents rarely lead to a cure and are associated with potentially severe side effects. Therefore, a strong need remains for more-efficacious and well-tolerated treatments that improve patients’ outcomes.


  • Which attributes most influence prescribers’ decisions for R/R Philadelphia chromosome-negative ALL?
  • How do current therapies such as Blincyto, Besponsa, and CAR T-cell agents perform on key treatment drivers and goals for this patient population?
  • What are the prevailing areas of unmet need and hidden opportunity in the treatment of R/R Philadelphia chromosome-negative ALL?
  • What trade-offs across key clinical attributes and price are acceptable to surveyed hematologist-oncologists for a novel therapy to treat R/R Philadelphia chromosome-negative ALL?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 61 U.S. and 30 European hematologist-oncologists fielded in February 2024

Key drugs: Blincyto, Besponsa, Kymriah, Tecartus


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.


The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

launch Related Market Assessment Reports